Experienced in Hyperparathyroidism

Evangelos Terpos

5 Marathonomahon Street, 
Drosia, ESYE21, GR 
Experienced in Hyperparathyroidism
5 Marathonomahon Street, 
Drosia, ESYE21, GR 
OverviewLocationsClinical Research

Overview

Evangelos Terpos practices in Drosia, Greece. Mr. Terpos is rated as an Experienced expert by MediFind in the treatment of Hyperparathyroidism. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 618 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hyperparathyroidism.

Gender
Male

Locations

5 Marathonomahon Street, Drosia, ESYE21 14572, Greece

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial DEFENCE (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial DEFENCE (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)
Enrollment Status: Completed
Publish Date: February 11, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 2
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drugs: ACY-241, Pomalidomide, Dexamethasone
Study Phase: Phase 1
View 1 Less Clinical Trial

618 Total Publications

The challenge of non-transplant eligible, newly diagnosed multiple myeloma.
The challenge of non-transplant eligible, newly diagnosed multiple myeloma.
Journal: Leukemia & lymphoma
Published: September 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Terpos's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 15 Distinguished Conditions
View All 16 Advanced Conditions
View All 55 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile